Methods for the treatment of respiratory depression
View Patent ↗This invention relates to compounds, pharmaceutical compositions and methods for use in the prevention and treatment of cerebral insufficiency, including enhancement of receptor functioning in synapses in brain networks responsible for basic and higher order behaviors. These brain networks, which are involved in regulation of breathing, and cognitive abilities related to memory impairment, such as is observed in a variety of dementias, in imbalances in neuronal activity between different brain regions, as is suggested in disorders such as Parkinson's disease, schizophrenia, respiratory depression, sleep apneas, attention deficit hyperactivity disorder and affective or mood disorders, and in disorders wherein a deficiency in neurotrophic factors is implicated, as well as in disorders of respiration such as overdose of an alcohol, an opiate, an opioid, a barbiturate, an anesthetic, or a nerve toxin, or where the respiratory depression results form a medical condition such as central sleep apnea, stoke-induced central sleep apnea, obstructive sleep apnea, congenital hypoventilation syndrome, obesity hypoventilation syndrome, sudden infant death syndrome, Rett syndrome, spinal cord injury, traumatic brain injury, Cheney-Stokes respiration, Ondines curse, Prader-Willi's syndrome and drowning, hi a particular aspect, the invention relates to bicyclic amide compounds useful for treatment of such conditions, and methods of using these compounds for such treatment.
1. A method of treating respiratory depression comprising administering to a patient in need thereof a compound according to formula A:
wherein:
W is oxygen;
X, Y and Z are independently selected from the group consisting of —N, or —CR,
wherein:
R is H, —Br, —Cl, —F, —CN, —NO 2 , —OR 1 , —SR 1 , —NR 1 2 , —C 1 -C 6 branched or un-branched alkyl, which may be un-substituted or substituted,
wherein:
R 1 is H, —C 1 -C 6 branched or un-branched alkyl which, may be un-substituted or substituted,
n is 0, 1, 2, 3, 4, 5
m is 0, 1, 2, 3, 4, 5
p is 1, 2, 3, 4, 5
R 2 and R 3 are each independently selected from H, a halogen (preferably F), —CN, —NO 2 , —OR 1 , —SR 1 , —NR 1 2 , CF 3 , OH, C═O, a —C 1 -C 6 branched or un-branched alkyl, which may be un-substituted or substituted, a —C 2 -C 6 branched or un-branched alkenyl, which may be un-substituted or substituted, a —C 2 -C 6 branched or un-branched alkynyl, which may be un-substituted or substituted, a —C 3 -C 7 cycloalkyl which may be un-substituted or substituted, an aryl which may be un-substituted or substituted, a heterocycle which may be un-substituted or substituted, a carboxyalkyl which may be un-substituted or substituted, a carboxyaryl which may be un-substituted or substituted, a carboxylheteroaryl which may be un-substituted or substituted, a sulfonylalkyl which may be un-substituted or substituted, a sulfonylaryl which may be un-substituted or substituted or a sulfonylheteroaryl which may be un-substituted or substituted, E and F are each independently selected from CH 2 m, CR 2 R 3 , A, CH 2 A, CR 2 ═CR 3 or are absent, with the proviso that E and F are not both absent;
G is CR 2 R 3 , A, CH 2 A, CR 2 ═CR 3 , CH 2 C═O, CH 2 CR 2 R 3 , or absent,
A is O, S, SO, SO 2 , C═O or CR 2 R 3 ;
or a pharmaceutically acceptable salt thereof.
2. The method according to claim 1 wherein said compound is according to the formula I:
wherein:
W is oxygen;
X, Y and Z are independently selected from the group consisting of —N, or —CR,
wherein:
R is H, —Br, —Cl, —F, —CN, —NO 2 , —OR 1 , —SR 1 , —NR 1 2 , —C 1 -C 6 branched or un-branched alkyl, which may be un-substituted or substituted,
wherein:
R 1 is H, —C 1 -C 6 branched or un-branched alkyl which, may be un-substituted or substituted,
n is 0-5
m is 0-5
p is 1-5
R 2 and R 3 are independently selected from H, a halogen (preferably F), —CN, —NO 2 , —OR 1 , —SR 1 , —NR 1 2 , CF 3 , OH, C═O, a —C 1 -C 6 branched or un-branched alkyl, which may be un-substituted or substituted, a —C 2 -C 6 branched or un-branched alkenyl, which may be un-substituted or substituted, a —C 2 -C 6 branched or un-branched alkynyl, which may be un-substituted or substituted, a —C 3 -C 7 cycloalkyl which may be un-substituted or substituted, an aryl which may be un-substituted or substituted, a heterocycle which may be un-substituted or substituted, a carboxyalkyl which may be un-substituted or substituted, a carboxyaryl which may be un-substituted or substituted, a carboxylheteroaryl which may be un-substituted or substituted, a sulfonylalkyl which may be un-substituted or substituted, a sulfonylaryl which may be un-substituted or substituted or a sulfonylheteroaryl which may be un-substituted or substituted, or a pharmaceutically acceptable salt thereof.
3. The method according to claim 1 wherein said compound is according to the formula II:
wherein:
W is oxygen, X, Y, and Z are independently selected from the group consisting of —N, or —CR, wherein: R is H, —Br, —Cl, —F, —CN, —NO 2 , —OR 1 , —SR 1 , —NR 1 2 , —C 1 -C 6 branched or un-branched alkyl, which may be un-substituted or substituted, wherein: R 1 is H, —C 1 -C 6 branched or un-branched alkyl, which, may be un-substituted or substituted,
n is 0-5
m is 0-5
p is 1-4
and R 2 and R 3 are independently selected from H, a halogen (preferably F), —CN, —NO 2 , —OR 1 , —SR 1 , —NR 1 2 , CF 3 , OH, C═O, a —C 1 -C 6 branched or un-branched alkyl, which may be un-substituted or substituted, —C 2 -C 6 branched or un-branched alkenyl, which may be un-substituted or substituted, —C 2 -C 6 branched or un-branched alkynyl, which may be un-substituted or substituted, —C 3 -C 7 cycloalkyl, which may be un-substituted or substituted, an aryl which may be un-substituted or substituted, a heterocycle which may be un-substituted or substituted, a carboxyalkyl which may be un-substituted or substituted, a carboxyaryl which may be un-substituted or substituted, a carboxylheteroaryl which may be un-substituted or substituted, a sulfonylalkyl which may be un-substituted or substituted, a sulfonylaryl which may be un-substituted or substituted, a sulfonylheteroaryl which may be un-substituted or substituted, or a pharmaceutically acceptable salt thereof.
4. The method according to claim 1 wherein said compound is according to formula III:
wherein:
W is oxygen, X, Y, and Z are independently selected from the group consisting of —N, or —CR, wherein: R is H, —Br, —Cl, —F, —CN, —NO 2 , —OR 1 , —SR 1 , —NR 1 2 , —C 1 -C 6 branched or un-branched alkyl, which may be un-substituted or substituted, wherein: R 1 is H, —C 1 -C 6 branched or un-branched alkyl, which, may be un-substituted or substituted,
A is O, S, SO, SO 2 , C═O or CR 2 R 3 ;
n is 0-5
m is 1-5
p is 1-5
and R 2 and R 3 are independently selected from H, a halogen (preferably F), —CN, —NO 2 , —OR 1 , —SR 1 , —NR 1 2 , CF 3 , OH, C═O, a —C 1 -C 6 branched or un-branched alkyl, which may be un-substituted or substituted, —C 2 -C 6 branched or un-branched alkenyl, which may be un-substituted or substituted, —C 2 -C 6 branched or un-branched alkynyl, which may be un-substituted or substituted, —C 3 -C 7 cycloalkyl, which may be un-substituted or substituted, an aryl which may be un-substituted or substituted, a heterocycle which may be un-substituted or substituted, a carboxyalkyl which may be un-substituted or substituted, a carboxyaryl which may be un-substituted or substituted, a carboxylheteroaryl which may be un-substituted or substituted, a sulfonylalkyl which may be un-substituted or substituted, a sulfonylaryl which may be un-substituted or substituted, a sulfonylheteroaryl which may be un-substituted or substituted, or a pharmaceutically acceptable salt thereof.
5. The method according to claim 1 wherein said compound is according to formula IV:
wherein:
W is oxygen, X, Y, and Z are independently selected from the group consisting of —N, or —CR, wherein: R is H, —Br, —Cl, —F, —CN, —NO 2 , —OR 1 , —SR 1 , —NR 1 2 , —C 1 -C 6 branched or un-branched alkyl, which may be un-substituted or substituted, wherein: R 1 is H, —C 1 -C 6 branched or un-branched alkyl, which, may be un-substituted or substituted,
A is O, S, SO, SO 2 , C═O or CR 2 R 3 ;
n=1-5
m=1-5
p=1-5
and R 2 and R 3 are independently selected from H, a halogen (preferably F), —CN, —NO 2 , —OR 1 , —SR 1 , —NR 1 2 , CF 3 , OH, C═O, a —C 1 -C 6 branched or un-branched alkyl, which may be un-substituted or substituted, —C 2 -C 6 branched or un-branched alkenyl, which may be un-substituted or substituted, —C 2 -C 6 branched or un-branched alkynyl, which may be un-substituted or substituted, —C 3 -C 7 cycloalkyl, which may be un-substituted or substituted, an aryl which may be un-substituted or substituted, a heterocycle which may be un-substituted or substituted, a carboxyalkyl which may be un-substituted or substituted, a carboxyaryl which may be un-substituted or substituted, a carboxylheteroaryl which may be un-substituted or substituted, a sulfonylalkyl which may be un-substituted or substituted, a sulfonylaryl which may be un-substituted or substituted, a sulfonylheteroaryl which may be un-substituted or substituted, or a pharmaceutically acceptable salt thereof.
6. The method according to claim 1 wherein
W is O;
X, Y and Z are CR;
R is H, F, Br, Cl, CN or NO 2 ;
E is CH 2 m or CH 2 A;
F is CH 2 m or CR 2 R 3 ;
R 2 and R 3 are H;
G is CH 2 A;
A is O;
m is 1;
n is 0; and
p is 1.
7. The method according to claim 1 wherein
W is O;
X, Y and Z are CR;
R is H;
E and F are CH 2 m;
G is CH 2 A;
A is O;
m is 1;
n is 0; and
p is 1.
8. The method according to claim 1 wherein
W is O;
X, Y and Z are CR;
R is H;
E is CH 2 A;
F is CH 2 m;
G is CH 2 A;
A is O;
m is 1;
n is 0; and
p is 1.
9. The method according to claim 1 wherein
W is O;
X, Y and Z are CR;
R is H;
E is CH 2 m;
F is CR 2 R 3 ;
R 2 and R 3 are H;
G is CH 2 A;
A is O;
m is 2;
n is 0; and
p is 1.
10. The method according to claim 2 wherein said compound is:
8-Azabicyclo[3.2.1]oct-8-yl([2,1,3]-benzoxadiazol-5-yl)methanone;
8-([2,1,3]-Benzoxadiazol-5-ylcarbonyl)-8-azabicyclo[3.2.1]octan-3-one;
[2,1,3]-Benzoxadiazol-5-yl(3,3-difluoro-8-azabicyclo[3.2.1]oct-8-yl)methanone;
endo-[2,1,3]-Benzoxadiazol-5-yl(3-hydroxy-8-azabicyclo[3.2.1]oct-8-yl)methanone;
exo-[2,1,3]-Benzoxadiazol-5-yl(3-hydroxy-8-azabicyclo[3.2.1]oct-8-yl)methanone;
2-Azabicyclo[2.2.1]hept-2-yl([2,1,3]-benzoxadiazol-5-yl)methanone;
1-Azabicyclo[2.2.1]hept-1-yl([2,1,3]-benzoxadiazol-5-yl)methanone;
2-Azabicyclo[2.2.2]oct-2-yl([2,1,3]-benzoxadiazol-5-yl)methanone; or
[2,1,3]-Benzoxadiazol-5-yl(5,6-dichloro-2-azabicyclo[2.2.1]hept-2-yl)methanone.
11. The method according to claim 3 wherein said compound is:
[2,1,3]-Benzoxadiazol-5-yl(3-fluoro-8-azabicyclo[3.2.1]oct-2-en-8-yl)methanone;
2-Azabicyclo[2.2.1]hept-5-en-2-yl([2,1,3]-benzoxadiazol-5-yl)methanone;
R-2-Azabicyclo[2.2.1]hept-5-en-2-yl([2,1,3]-benzoxadiazol-5-yl)methanone; or
S-2-Azabicyclo[2.2.1]hept-5-en-2-yl([2,1,3]-benzoxadiazol-5-yl)methanone.
12. The method according to claim 5 wherein said compound is:
[2,1,3]-Benzoxadiazol-5-yl(2-oxa-5azabicyclo[2.2.1]hept-5-yl)methanone.
13. The method according to claim 1 wherein said compound is combined with an opiate or opioid analgesic.
14. The method according to claim 1 wherein said compound is combined with an anesthetic agent.
15. The method according to claim 14 wherein said anesthetic agent is propofol or a barbiturate.